Screener
Bristol-Myers Squibb BMY Eliquis — Total Revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Bristol-Myers Squibb in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The source filing: Bristol-Myers Squibb’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 11:10 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000014272-26-000020
| Dollars in millions | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Other Growth products(a) | 653 | 557 | 1,234 | 1,063 |
| Total Growth Portfolio | 7,560 | 6,596 | 13,787 | 12,159 |
| Legacy Portfolio | ||||
| Eliquis | 4,481 | 3,680 | 8,617 | 7,245 |
| Revlimid | 425 | 838 | 773 | 1,774 |
| Pomalyst/Imnovid | 204 | 708 | 717 | 1,366 |
| Sprycel | 88 | 120 | 160 | 295 |
| Abraxane | 55 | 105 | 105 | 210 |
Item 1. FINANCIAL STATEMENTS
FAQ
- What is Bristol-Myers Squibb's eliquis — total revenues?
- Bristol-Myers Squibb (BMY) reported eliquis — total revenues of $4.48B in Q2 2026.
- How has Bristol-Myers Squibb's eliquis — total revenues changed year-over-year?
- Bristol-Myers Squibb's eliquis — total revenues increased by 21.8% year-over-year, from $3.68B to $4.48B.
- What is the long-term trend for Bristol-Myers Squibb's eliquis — total revenues?
- Over 4 years (2021 to 2025), Bristol-Myers Squibb's eliquis — total revenues has grown at a 7.6% compound annual growth rate (CAGR), from $10.76B to $14.44B.
- What does eliquis — total revenues mean?
- This metric represents the total global net sales generated by the anticoagulant medication Eliquis. As a cornerstone product in the company's cardiovascular portfolio, it serves as a primary driver of top-line growth and cash flow generation. Monitoring this revenue stream is critical for assessing the company's market share in the oral anticoagulant space and its ability to withstand generic competition or pricing pressures.
Ask your AI about Bristol-Myers Squibb's eliquis — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude